New hope for stubborn arthritis: experimental drug targets immune cells
NCT ID NCT06994143
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called CLN-978 in about 37 people whose rheumatoid arthritis has not responded to standard treatments. The goal is to see if the drug is safe and can control the disease by reducing certain immune cells (B cells) that drive inflammation. Participants will receive the drug and be monitored for side effects and changes in their condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario A Gemelli
RECRUITINGRome, 00168, Italy
Contact Phone: •••-•••-••••
-
University Hospital Erlangen
RECRUITINGErlangen, 91054, Germany
Contact Phone: •••-•••-••••
-
University Hospital Heidelberg
RECRUITINGHeidelberg, 69120, Germany
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a traditional chinese herb tame stubborn rheumatoid arthritis?
- Could a common herb ease rheumatoid arthritis?
- New pill aims to tame rheumatoid arthritis inflammation
- Blood test could help rheumatoid arthritis patients safely reduce medication
- Will a new drug form work the same? study tests two versions of SKI-O-703
- Morning or evening? timing your RA pill could boost relief